BioArctic AB (publ) (BIOABS.XC)
| Previous close | 279.80 |
| Open | 288.40 |
| Bid | 235.40 x 0 |
| Ask | 239.80 x 0 |
| Day's range | 279.80 - 279.80 |
| 52-week range | 278.60 - 299.80 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 23.841B |
| Beta (5Y monthly) | -0.15 |
| PE ratio (TTM) | 96.15 |
| EPS (TTM) | 2.91 |
| Earnings date | 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 10 May 2019 |
| 1y target est | N/A |
Simply Wall St.Swedish Exchange Highlights: Three Growth Companies With High Insider Ownership
As global markets exhibit varied responses to economic signals, Sweden's market remains a focal point for investors seeking stability and growth potential. In this context, companies with high insider ownership can be particularly appealing as they often demonstrate a deep commitment from those who know the business best. In light of the current market conditions, where investor sentiment is cautiously optimistic amid economic adjustments, stocks with substantial insider stakes might offer a...
PR NewswireLeqembi® (lecanemab) launched in China
BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced today that Leqembi® (brand name in China: "乐意保®", generic name: lecanemab) has been launched in China. Leqembi received approval in January 2024 as a treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. China is the third country to launch Leqembi following the United States and Japan.
Simply Wall St.Swedish Exchange Growth Companies With Minimum 28% Insider Ownership
As global markets show signs of resilience, with indices like the S&P 500 reaching new highs, investors are keenly observing trends and shifts across various regions. In Sweden, growth companies with high insider ownership are garnering attention as potentially stable investments in a fluctuating economic landscape.
